|
1
|
Li Z, Duan Z, Jia K, Yao Y, Liu K, Qiao Y,
Gao Q, Yang Y, Li G and Shang A: A combined risk score model to
assess prognostic value in patients with soft tissue sarcomas.
Cells. 11:40772022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gamboa AC, Gronchi A and Cardona K:
Soft-tissue sarcoma in adults: An update on the current state of
histiotype-specific management in an era of personalized medicine.
CA Cancer J Clin. 70:200–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ardakani AHG, Woollard A, Ware H and Gikas
P: Soft tissue sarcoma: Recognizing a rare disease. Cleve Clin J
Med. 89:73–80. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen HH, Zhang TN, Zhang FY and Zhang T:
Non-coding RNAs in drug and radiation resistance of bone and
soft-tissue sarcoma: A systematic review. Elife. 11:e796552022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu R, Qi L, Ren X, Zhang W, Li C, Liu Z,
Tu C and Li Z: Integrated analysis of TME and hypoxia identifies a
classifier to predict prognosis and therapeutic biomarkers in soft
tissue sarcomas. Cancers (Basel). 14:56752022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gu HY, Lin LL, Zhang C, Yang M, Zhong HC
and Wei RX: The potential of five immune-related prognostic genes
to predict survival and response to immune checkpoint inhibitors
for soft tissue sarcomas based on multi-omic study. Front Oncol.
10:13172020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chibon F, Lagarde P, Salas S, Pérot G,
Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B,
et al: Validated prediction of clinical outcome in sarcomas and
multiple types of cancer on the basis of a gene expression
signature related to genome complexity. Nat Med. 16:781–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Proost JH and Eleveld DJ: Performance of
an iterative two-stage bayesian technique for population
pharmacokinetic analysis of rich data sets. Pharm Res.
23:2748–2759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Wang T, Gong HY, Jiang RY, Zhou
W, Sun HT, Huang R, Wang Y, Wu Z, Xu W, et al: A novel molecular
classification method for osteosarcoma based on tumor cell
differentiation trajectories. Bone Res. 11:12023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lepucki A, Orlińska K, Mielczarek-Palacz
A, Kabut J, Olczyk P and Komosińska-Vassev K: The role of
extracellular matrix proteins in breast cancer. J Clin Med.
11:12502022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song Y, Ma X, Zhang M, Wang M, Wang G, Ye
Y and Xia W: Ezrin mediates invasion and metastasis in
tumorigenesis: A review. Front Cell Dev Biol. 8:5888012020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rømer AMA, Thorseth ML and Madsen DH:
Immune modulatory properties of collagen in cancer. Front Immunol.
12:7914532021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan JY, Gong HY, Han S, Liu JL, Wu ZP,
Wang ZH and Wang T: GALNT5 functions as a suppressor of ferroptosis
and a predictor of poor prognosis in pancreatic adenocarcinoma. Am
J Cancer Res. 13:4579–4596. 2023.PubMed/NCBI
|
|
16
|
Crombé A, Roulleau-Dugage M and Italiano
A: The diagnosis, classification, and treatment of sarcoma in this
era of artificial intelligence and immunotherapy. Cancer Commun
(Lond). 42:1288–1313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lynch MM, Alexiev BA, Schroeder BA and
Pollack SM: Combinations of chemotherapy and PD-1/PD-L1 inhibitors
in sarcoma. Curr Treat Options Oncol. 23:1861–1876. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Milunsky A, Baldwin C, Zhang X, Primack D,
Curnow A and Milunsky J: Diagnosis of chronic intestinal
pseudo-obstruction and megacystis by sequencing the ACTG2 gene. J
Pediatr Gastroenterol Nutr. 65:384–387. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao B, Baloch Z, Ma Y, Wan Z, Huo Y, Li F
and Zhao Y: Identification of potential key genes and pathways in
early-onset colorectal cancer through bioinformatics analysis.
Cancer Control. 26:10732748198312602019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang G, Wu D, Guo M and Li H: LncRNA
MIR497HG inhibits colorectal cancer progression by the
miR-3918/ACTG2 axis. J Genet. 101:272022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Y, Liu ZG, Shi MQ, Yu HZ, Jiang XY,
Yang AH, Fu XS, Xu Y, Yang S, Ni H, et al: Identification of ACTG2
functions as a promoter gene in hepatocellular carcinoma cells
migration and tumor metastasis. Biochem Biophys Res Commun.
491:537–544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis LE, Nusser KD, Przybyl J,
Pittsenbarger J, Hofmann NE, Varma S, Vennam S, Debiec-Rychter M,
van de Rijn M and Davare MA: Discovery and characterization of
recurrent, targetable ALK fusions in leiomyosarcoma. Mol Cancer
Res. 17:676–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beck AH, Lee CH, Witten DM, Gleason BC,
Edris B, Espinosa I, Zhu S, Li R, Montgomery KD, Marinelli RJ, et
al: Discovery of molecular subtypes in leiomyosarcoma through
integrative molecular profiling. Oncogene. 29:845–854. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jankovic-Karasoulos T, Bianco-Miotto T,
Butler MS, Butler LM, McNeil CM, O'Toole SA, Millar EKA, Sakko AJ,
Ruiz AI, Birrell SN, et al: Elevated levels of tumour
apolipoprotein D independently predict poor outcome in breast
cancer patients. Histopathology. 76:976–987. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Qin Y, Li D and Yang Y: A risk
prediction model mediated by genes of APOD/APOC1/SQLE associates
with prognosis in cervical cancer. BMC Womens Health. 22:5342022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ruchong P, Haiping T and Xiang W: A
five-gene prognostic nomogram predicting disease-free survival of
differentiated thyroid cancer. Dis Markers. 2021:55107802021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Palmerini E, Gambarotti M, Staals EL,
Zanella L, Sieberova G, Longhi A, Cesari M, Bonarelli S, Picci P,
Ruggieri P, et al: Fibrosarcomatous changes and expression of CD34+
and apolipoprotein-D in dermatofibrosarcoma protuberans. Clin
Sarcoma Res. 2:42012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Green BB, Kappil M, Lambertini L,
Armstrong DA, Guerin DJ, Sharp AJ, Lester BM, Chen J and Marsit CJ:
Expression of imprinted genes in placenta is associated with infant
neurobehavioral development. Epigenetics. 10:834–841. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mai X, Mai Q, Li T and Zhou C: Dynamic
expression patterns of imprinted genes in human embryonic stem
cells following prolonged passaging and differentiation. J Assist
Reprod Genet. 28:315–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang SH, Oh SY, Lee HJ, Kwon TG, Kim JW,
Lee ST, Choi SY and Hong SH: Cancer-associated fibroblast subgroups
showing differential promoting effect on HNSCC progression. Cancers
(Basel). 13:6542021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Long R, Liu Z, Li J and Yu H: COL6A6
interacted with P4HA3 to suppress the growth and metastasis of
pituitary adenoma via blocking PI3K-Akt pathway. Aging (Albany NY).
11:8845–8859. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qiao H, Feng Y and Tang H: COL6A6 inhibits
the proliferation and metastasis of non-small cell lung cancer
through the JAK signalling pathway. Transl Cancer Res.
10:4514–4522. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma Y, Qiu M, Guo H, Chen H, Li J, Li X and
Yang F: Comprehensive analysis of the immune and prognostic
implication of COL6A6 in lung adenocarcinoma. Front Oncol.
11:6334202021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Skenteris NT, Seime T, Witasp A, Karlöf E,
Wasilewski GB, Heuschkel MA, Jaminon AMG, Oduor L, Dzhanaev R,
Kronqvist M, et al: Osteomodulin attenuates smooth muscle cell
osteogenic transition in vascular calcification. Clin Transl Med.
12:e6822022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hamaya E, Fujisawa T and Tamura M:
Osteoadherin serves roles in the regulation of apoptosis and growth
in MC3T3-E1 osteoblast cells. Int J Mol Med. 44:2336–2344.
2019.PubMed/NCBI
|
|
36
|
Papadaki V, Asada K, Watson JK, Tamura T,
Leung A, Hopkins J, Dellett M, Sasai N, Davaapil H, Nik-Zainal S,
et al: Two secreted proteoglycans, activators of urothelial
cell-cell adhesion, negatively contribute to bladder cancer
initiation and progression. Cancers (Basel). 12:33622020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nallasamy P, Nimmakayala RK, Parte S, Are
AC, Batra SK and Ponnusamy MP: Tumor microenvironment enriches the
stemness features: The architectural event of therapy resistance
and metastasis. Mol Cancer. 21:2252022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodrigues FS, Ciccarelli FD and Malanchi
I: Reflected stemness as a potential driver of the tumour
microenvironment. Trends Cell Biol. 32:979–987. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao Y, Fan WH, Song Z, Lou H and Kang X:
Comparison of circulating tumor cell (CTC) detection rates with
epithelial cell adhesion molecule (EpCAM) and cell surface vimentin
(CSV) antibodies in different solid tumors: A retrospective study.
PeerJ. 9:e107772021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ventura E, Xie C, Buraschi S, Belfiore A,
Iozzo RV, Giordano A and Morrione A: Complexity of progranulin
mechanisms of action in mesothelioma. J Exp Clin Cancer Res.
41:3332022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fromme JE and Zigrino P: The role of
extracellular matrix remodeling in skin tumor progression and
therapeutic resistance. Front Mol Biosci. 9:8643022022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kolesnikoff N, Chen CH and Samuel MS:
Interrelationships between the extracellular matrix and the immune
microenvironment that govern epithelial tumour progression. Clin
Sci (Lond). 136:361–377. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abu Zaid MI, Radovich M, Althouse S, Liu
H, Spittler AJ, Solzak J, Badve S and Loehrer PJ Sr: A phase II
study of buparlisib in relapsed or refractory thymomas. Front
Oncol. 12:8913832022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Heudel P, Frenel JS, Dalban C, Bazan F,
Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P,
Pautier P, et al: Safety and efficacy of the mTOR inhibitor,
vistusertib, combined with anastrozole in patients with hormone
receptor-positive recurrent or metastatic endometrial cancer: The
VICTORIA multicenter, open-label, phase 1/2 randomized clinical
trial. JAMA Oncol. 8:1001–1009. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Savas P, Lo LL, Luen SJ, Blackley EF,
Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, et al:
Alpelisib monotherapy for PI3K-altered, pretreated advanced breast
cancer: A phase II study. Cancer Discov. 12:2058–2073. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu C, Wang Z, Zhang L, Feng Y, Lv J, Wu Z,
Yang R, Wu T, Li J, Zhou R, et al: Periostin promotes the
proliferation and metastasis of osteosarcoma by increasing cell
survival and activates the PI3K/Akt pathway. Cancer Cell Int.
22:342022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu RH, Zhang XY, Xu W, Li ZK and Zhu XD:
Apolipoprotein D alleviates glucocorticoid-induced osteogenesis
suppression in bone marrow mesenchymal stem cells via the PI3K/Akt
pathway. J Orthop Surg Res. 15:3072020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guntur AR, Rosen CJ and Naski MC:
N-cadherin adherens junctions mediate osteogenesis through PI3K
signaling. Bone. 50:54–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Patente TA, Pinho MP, Oliveira AA,
Evangelista GCM, Bergami-Santos PC and Barbuto JAM: Human dendritic
cells: Their heterogeneity and clinical application potential in
cancer immunotherapy. Front Immunol. 9:31762019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu D, Heij LR, Czigany Z, Dahl E, Lang
SA, Ulmer TF, Luedde T, Neumann UP and Bednarsch J: The role of
tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin
Cancer Res. 41:1272022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
